Most of Israel "Izzy" Englander's favorite stocks these days are technology leaders. At least that's the conclusion you'd ...
Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant Prairie, ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
BioAge (BIOA) stock cratered 70% Friday evening after the company said it was discontinuing a Phase 2 study for its ...
BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly's tirzepatide for the treatment of obesity.
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
Viking Therapeutics shows strong data with VK2735, a potential competitor to major drugs. Discover why VKTX stock is a ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
According to projections, the global market for obesity drugs could be worth nearly $14 billion by 2032. Zepbound has already ...
Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...